Knowledge and perceptions about Dolutegravir and Dolutegravir counselling: a qualitative study among women living with HIV.
Adherence
Antiretroviral therapy
Dolutegravir
Efavirenz
Neural tube defects
Journal
BMC women's health
ISSN: 1472-6874
Titre abrégé: BMC Womens Health
Pays: England
ID NLM: 101088690
Informations de publication
Date de publication:
09 09 2023
09 09 2023
Historique:
received:
02
11
2022
accepted:
31
08
2023
medline:
11
9
2023
pubmed:
10
9
2023
entrez:
9
9
2023
Statut:
epublish
Résumé
In 2018, the Malawi Ministry of Health adopted the recommendation to switch first-line antiretroviral therapy (ART) from an efavirenz (EFV)-based to a dolutegravir (DTG)-based regimen. Little is known about patients' experience during this transition. We conducted a qualitative study to explore DTG-related counselling challenges among providers of HIV care and factors influencing regimen switching or non-switching among women living with HIV in Lilongwe, Malawi. Between February-July 2020, we recruited participants who took part in DTG counselling on reasons to switch, side effects, and benefits from two government health facilities providing HIV care: Area 18 health centre and Bwaila district hospital in Lilongwe, Malawi. We purposively sampled and interviewed 8 women living with HIV who remained on an EFV-based regimen after counselling, 10 women who switched to a DTG-based regimen, and 10 HIV care providers who provided counselling about ART switching. In-depth interviews were used to explore patient's perceptions of DTG, factors affecting the decision to switch, and both patient and provider experience with counselling. Interview data was coded for themes using inductive and deductive codes. Interviews were conducted until thematic saturation was achieved. Data matrices were used for analysis and thematic extraction. Most women in both groups were well versed on DTG's potential side effects and felt well counselled on the benefits of switching, such as quicker viral load suppression. Many women associated DTG with birth defects and expressed concern. However, the primary reason for not switching was concern with how the new medication would be tolerated, especially when they were satisfied with their current regimen. Almost all providers expressed difficulty providing DTG counselling. Primary reasons included feeling inadequately trained and/or not having resources to use during counselling, such as diagrams or brochures. DTG counselling was well accepted by women; however, some felt that their concerns were not fully addressed. Providers reflected this sentiment in that they did not feel adequately trained or well-equipped to provide adequate counselling. Training on counselling for new ART regimens should be intensified and utilize patient-centered educational materials to address the concerns raised by both patients and health care providers.
Identifiants
pubmed: 37689628
doi: 10.1186/s12905-023-02630-7
pii: 10.1186/s12905-023-02630-7
pmc: PMC10492391
doi:
Substances chimiques
dolutegravir
DKO1W9H7M1
efavirenz
JE6H2O27P8
Benzoxazines
0
Anti-Retroviral Agents
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
478Subventions
Organisme : FIC NIH HHS
ID : D43 TW010060
Pays : United States
Informations de copyright
© 2023. BioMed Central Ltd., part of Springer Nature.
Références
BMC Infect Dis. 2021 Nov 13;21(1):1154
pubmed: 34774018
Am Fam Physician. 2011 Oct 1;84(7):780-4
pubmed: 22010616
BMC Public Health. 2019 Oct 28;19(1):1382
pubmed: 31660947
N Engl J Med. 2019 Aug 29;381(9):827-840
pubmed: 31329379
Cost Eff Resour Alloc. 2019 Sep 23;17:20
pubmed: 31572067
Lancet HIV. 2018 Jul;5(7):e400-e404
pubmed: 29884404
BMC Health Serv Res. 2019 Jun 3;19(1):350
pubmed: 31159780
J Biol Chem. 2019 Oct 11;294(41):15137-15157
pubmed: 31467082
Afr J Prim Health Care Fam Med. 2016 Apr 26;8(2):e1-6
pubmed: 27380841
Am J Public Health. 2015 Apr;105(4):665-9
pubmed: 25713962
PLoS One. 2021 Feb 25;16(2):e0247583
pubmed: 33630952
S Afr Med J. 2016 Dec 21;107(1):28-30
pubmed: 28112085
Lancet HIV. 2019 Feb;6(2):e72-e73
pubmed: 30503326